Anti-ACE-1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the catalytic domain of human angiotensin-converting enzyme, validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Dog, Pig
UniProt
P12821
Size
100ug
Cat. #
RP3ACE1

In stock

SKU
RP-ACE1

Options

As low as: $130.00

Target Overview

Angiotensin-converting enzyme (ACE, EC 3.4.15.1) is a zinc-dependent dipeptidyl carboxypeptidase that catalyzes the removal of C-terminal dipeptides from circulating peptide hormones. The enzyme is anchored to the cell membrane via a transmembrane domain and consists of two homologous catalytic domains, each containing an active site with distinct substrate preferences. ACE plays a central role in cardiovascular physiology by converting angiotensin I to the potent vasoconstrictor angiotensin II and by inactivating the vasodilator bradykinin, thereby regulating blood pressure and fluid homeostasis. Beyond the renin-angiotensin system, ACE cleaves neuropeptides including enkephalins, substance P, and neurotensin, contributing to modulation of synaptic transmission and pain signaling. The enzyme is also expressed as CD143 on endothelial cells and serves as a clinical target for ACE inhibitors in hypertension therapy. Researchers study ACE in contexts spanning renal physiology, cardiovascular disease, neurochemistry, and reproductive biology. The human enzyme (UniProt P12821) comprises 1,306 amino acids and exists in both membrane-bound and soluble forms following proteolytic cleavage.

Background

ACE functions as the rate-limiting enzyme in angiotensin II production, converting the decapeptide angiotensin I to the octapeptide angiotensin II by cleaving the C-terminal His-Leu dipeptide. This activity is mediated by two catalytic domains (N-domain and C-domain), which exhibit overlapping but non-identical substrate specificity. The C-domain preferentially processes angiotensin I, while the N-domain more efficiently cleaves bradykinin and certain neuropeptides. ACE-mediated inactivation of bradykinin, a vasodilator and inflammatory mediator, contributes to the enzyme's net pressor effect. In the central and peripheral nervous systems, ACE degrades enkephalin pentapeptides (Met-enkephalin and Leu-enkephalin) and other opioid peptides, influencing pain perception and neurotransmission. ACE is constitutively expressed on vascular endothelial cells, epithelial brush borders in the kidney and intestine, and in the male reproductive tract, where a testis-specific isoform regulates sperm maturation. ACE has been a therapeutic target since the development of captopril and other ACE inhibitors for hypertension and heart failure. Recent research continues to explore ACE biology in diverse contexts. Studies have examined ACE inhibitory peptides derived from food proteins, including plant sources such as muskmelon seed hydrolysates, which demonstrate variable potency against the enzyme in vitro. The renin-angiotensin system, including ACE, has also been investigated in relation to immune modulation and complement activation in renal pathology. Continued investigation of ACE substrate specificity, tissue-specific expression patterns, and inhibitor pharmacology informs both basic physiology and translational medicine. Triple Point Biologics offers four rabbit polyclonal antibodies targeting ACE-1, raised against amino acid sequences spanning the catalytic domain. These reagents are validated for Western blot applications in human samples, with predicted cross-reactivity in mouse, rat, non-human primate, canine, and porcine species.

References

  1. Aljallah B (2026) Preparation and assessment of ACE-inhibitory hydrolysates derived from muskmelon (Cucumis melo) seed protein utilising crude and activated charcoal-purified enzyme from Wrightia tinctoria. Nat Prod Res. PubMed · DOI
  2. Ergun G et al (2026) Clinical significance of serum complement levels and C3/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications. Ren Fail. PubMed · DOI
  3. UniProt Consortium. UniProt entry P12821 (ACE_HUMAN). Available at https://www.uniprot.org/uniprotkb/P12821

Additional Specifications

Gene Symbol ACE
UniProt ID P12821
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Dog, Pig
Pack Size 100ug
Immunogen (Amino Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 40-624.
Immunogen (Carboxy Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 40-624.
Immunogen (Carboxy Catalytic domain)Synthetic peptide corresponding to the Carboxy Catalytic domain of human ACE-1 (UniProt P12821).
Immunogen (Cytoplasmic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1278-1306.
Alternate Names ACE, Angiotensin-converting enzyme, EC 3.4.15.1, Dipeptidyl carboxypeptidase I, Kininase II, CD143, ACE1, DCP1, Angiotensin-converting enzyme soluble form

Frequently Asked Questions

What molecular weight should I expect for ACE-1 on a Western blot?

Somatic ACE (sACE), the predominant isoform in endothelial and epithelial tissues, runs at approximately 170 kDa due to extensive N-linked glycosylation; the deglycosylated polypeptide is closer to 150 kDa. Testicular ACE (tACE), expressed only in male germ cells, contains a single catalytic domain and migrates near 90–110 kDa depending on glycosylation state. A soluble cleaved form released by ACE secretase can appear around 160 kDa in serum and conditioned media. Run reducing SDS-PAGE on 7.5% or 4–15% gradient gels; higher-percentage gels compress the resolution in this MW range.

What is the recommended starting dilution for Western blot?

Start at 1:1000 in 5% non-fat milk or BSA in TBST, overnight at 4°C. For lysates with lower ACE expression (e.g., whole brain, non-endothelial cell lines), titrate down to 1:500. For high-expressing samples such as lung, kidney cortex, or HUVEC lysates, 1:2000–1:5000 is often sufficient. Load 20–40 µg total protein per lane. Because ACE is heavily glycosylated, avoid boiling samples above 70°C for more than 5 minutes — aggregation in the stacking gel is a common cause of signal loss at the expected MW.

Does this antibody distinguish somatic ACE from testicular ACE?

The immunogen spans a region present in both isoforms, so the antibody detects sACE and tACE. The two are easily distinguished by MW (~170 kDa versus ~100 kDa) and tissue distribution: tACE is restricted to post-meiotic male germ cells, while sACE dominates in vascular endothelium, kidney brush border, lung, and monocytes/macrophages. If you need isoform specificity, pair this antibody with a tACE-specific reagent raised against the unique N-terminal 67 residues of the testicular form, or use testis versus somatic tissue side-by-side as discriminating controls.

What positive control tissues or cell lines work well?

Human lung and kidney lysates are reliable high-expression controls for sACE. Among cell lines, HUVECs, HMEC-1, and Caco-2 (apical brush border) give strong signal. SW480 and HEK293 stably transfected with ACE constructs are useful for overexpression validation. For IHC, human kidney sections show characteristic brush border staining of proximal tubules and vascular endothelial labelling. Negative controls: ACE-knockdown HUVECs or lysates from cells pretreated with ACE-targeting siRNA. Captopril or lisinopril treatment does not reduce ACE protein levels and is not a suitable knockdown control.

Will this antibody cross-react with mouse or rat ACE?

Reactivity is validated in human. Mouse, rat, pig, dog, and Pan troglodytes reactivity is predicted based on sequence homology across the immunogen region (typically >85% identity for the mammalian orthologs listed), but has not been empirically confirmed by TPB. If you are working in mouse or rat, run a pilot blot against a known positive tissue (mouse lung or rat kidney) alongside human lung lysate before committing to a full experiment. Report back — confirmed cross-reactivity data from end users feeds into our validation database.

Can I use this antibody for immunoprecipitation or ACE activity assays?

The antibody is validated for Western blot. IP has not been formally validated, but rabbit polyclonals against extracellular ACE epitopes generally perform in native IP; expect to use 2–5 µg per mg of lysate and pre-clear thoroughly given the glycoprotein's tendency to bind non-specifically. For activity assays, immunocapture followed by fluorogenic substrate (e.g., Mca-RPPGFSAFK(Dnp)-OH or Hip-His-Leu) is feasible, but confirm the antibody does not occlude either catalytic domain by comparing captured versus total activity.

Why am I seeing multiple bands or a smear around 170 kDa?

ACE is heavily N-glycosylated at up to 17 sites, producing tissue-specific glycoforms that migrate as a doublet or diffuse band between 150 and 180 kDa. This is genuine signal, not degradation. Treatment with PNGase F collapses the bands to ~150 kDa and is a useful confirmation. Additional bands at ~90 kDa in testis samples represent tACE. Bands below 100 kDa in non-testis samples may indicate proteolytic cleavage during lysis — include 1 mM PMSF, EDTA-free protease inhibitors, and keep lysates cold. Avoid repeated freeze-thaw of membrane preparations.

How should I store the antibody and how stable is it?

Store at -20°C for long-term (up to 12 months from receipt) in the supplied buffer. For working stocks used within 4 weeks, 4°C is acceptable. Aliquot on first thaw into 5–10 µL volumes to avoid repeated freeze-thaw cycles, which degrade polyclonal performance over time. Do not store at -80°C unless you plan to thaw only once — the buffer is not optimized for ultra-low temperature cycling. If precipitation appears after thawing, centrifuge briefly at 10,000 × g and use the supernatant; activity is generally retained.

Western blot validation for RP-ACE1 — 3 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

ACE-1: Amino Catalytic domain — WB validation
WB · Panel 1 ACE-1: Amino Catalytic domain
ACE-1: Cytoplasmic domain — WB validation
WB · Panel 2 ACE-1: Cytoplasmic domain
ACE-1: Carboxy Catalytic domain — WB validation
WB · Panel 3 ACE-1: Carboxy Catalytic domain

Custom validation studies available on request — contact us.

Also known as:

  • ACE
  • Angiotensin-converting enzyme
  • EC 3.4.15.1
  • Dipeptidyl carboxypeptidase I
  • Kininase II
  • CD143
  • ACE1
  • DCP1
  • Angiotensin-converting enzyme soluble form
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →